Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Preleukemia 1Plasmacytoma 1Paraproteinemias 1Multiple Myeloma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 116Cyclophosphamide 104venetoclax 89fludarabine 85Azacitidine 81fludarabine phosphate 70Rituximab 59Filgrastim 44Peripheral Blood Stem Cell Transplantation 39Methotrexate 39Dexamethasone 35Decitabine 35Busulfan 32Etoposide 31Tacrolimus 30Mycophenolic Acid 29Granulocyte Colony-Stimulating Factor 28Lenalidomide 27Whole-Body Irradiation 26Idarubicin 26Vincristine 25Melphalan 24Cyclosporine 24Clofarabine 24Mitoxantrone 22Bortezomib 21Alemtuzumab 21ibrutinib 19ruxolitinib 17aldesleukin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × filanesib × Other hematologic neoplasm × Clear all
NCT00637052 2021-02-08

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Pfizer

Phase 1/2 Completed
36 enrolled
Other hematologic neoplasm

Preleukemia, Leukemia, Myeloid, Acute

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡